Logo image of EOLS

EVOLUS INC (EOLS) Stock Fundamental Analysis

NASDAQ:EOLS - Nasdaq - US30052C1071 - Common Stock - Currency: USD

11.31  -0.34 (-2.92%)

After market: 11.33 +0.02 (+0.18%)

Fundamental Rating

3

Taking everything into account, EOLS scores 3 out of 10 in our fundamental rating. EOLS was compared to 198 industry peers in the Pharmaceuticals industry. EOLS has a bad profitability rating. Also its financial health evaluation is rather negative. EOLS is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EOLS had negative earnings in the past year.
EOLS had a negative operating cash flow in the past year.
In the past 5 years EOLS always reported negative net income.
In the past 5 years EOLS always reported negative operating cash flow.
EOLS Yearly Net Income VS EBIT VS OCF VS FCFEOLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of EOLS (-21.68%) is better than 60.10% of its industry peers.
With a Return On Equity value of -913.07%, EOLS is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -21.68%
ROE -913.07%
ROIC N/A
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EOLS Yearly ROA, ROE, ROICEOLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

Looking at the Gross Margin, with a value of 68.46%, EOLS is in the better half of the industry, outperforming 73.23% of the companies in the same industry.
In the last couple of years the Gross Margin of EOLS has declined.
The Profit Margin and Operating Margin are not available for EOLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
EOLS Yearly Profit, Operating, Gross MarginsEOLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

EOLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
EOLS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for EOLS has been increased compared to 5 years ago.
EOLS has a better debt/assets ratio than last year.
EOLS Yearly Shares OutstandingEOLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
EOLS Yearly Total Debt VS Total AssetsEOLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -0.55, we must say that EOLS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.55, EOLS is in line with its industry, outperforming 54.04% of the companies in the same industry.
A Debt/Equity ratio of 22.00 is on the high side and indicates that EOLS has dependencies on debt financing.
EOLS's Debt to Equity ratio of 22.00 is on the low side compared to the rest of the industry. EOLS is outperformed by 84.34% of its industry peers.
Industry RankSector Rank
Debt/Equity 22
Debt/FCF N/A
Altman-Z -0.55
ROIC/WACCN/A
WACC10.5%
EOLS Yearly LT Debt VS Equity VS FCFEOLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

EOLS has a Current Ratio of 2.40. This indicates that EOLS is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.40, EOLS perfoms like the industry average, outperforming 46.46% of the companies in the same industry.
EOLS has a Quick Ratio of 2.21. This indicates that EOLS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of EOLS (2.21) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 2.21
EOLS Yearly Current Assets VS Current LiabilitesEOLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

7

3. Growth

3.1 Past

EOLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.68%, which is quite impressive.
The Revenue has grown by 31.76% in the past year. This is a very strong growth!
The Revenue has been growing by 50.14% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)59.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.33%
Revenue 1Y (TTM)31.76%
Revenue growth 3Y38.74%
Revenue growth 5Y50.14%
Sales Q2Q%29.42%

3.2 Future

EOLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 62.54% yearly.
The Revenue is expected to grow by 25.87% on average over the next years. This is a very strong growth
EPS Next Y75.25%
EPS Next 2Y124.19%
EPS Next 3Y102.89%
EPS Next 5Y62.54%
Revenue Next Year31.82%
Revenue Next 2Y32.41%
Revenue Next 3Y29.86%
Revenue Next 5Y25.87%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
EOLS Yearly Revenue VS EstimatesEOLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
EOLS Yearly EPS VS EstimatesEOLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EOLS. In the last year negative earnings were reported.
Also next year EOLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EOLS Price Earnings VS Forward Price EarningsEOLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EOLS Per share dataEOLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as EOLS's earnings are expected to grow with 102.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y124.19%
EPS Next 3Y102.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EOLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOLUS INC

NASDAQ:EOLS (4/28/2025, 8:05:19 PM)

After market: 11.33 +0.02 (+0.18%)

11.31

-0.34 (-2.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-04 2025-03-04/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners74.65%
Inst Owner Change0.48%
Ins Owners1.96%
Ins Owner Change0.39%
Market Cap719.20M
Analysts85
Price Target23.72 (109.73%)
Short Float %14.8%
Short Ratio9.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.84%
Min EPS beat(2)-60.88%
Max EPS beat(2)3.2%
EPS beat(4)3
Avg EPS beat(4)-4.28%
Min EPS beat(4)-60.88%
Max EPS beat(4)24.59%
EPS beat(8)6
Avg EPS beat(8)-9.73%
EPS beat(12)9
Avg EPS beat(12)-4.07%
EPS beat(16)12
Avg EPS beat(16)1.52%
Revenue beat(2)0
Avg Revenue beat(2)-2.44%
Min Revenue beat(2)-3.78%
Max Revenue beat(2)-1.09%
Revenue beat(4)1
Avg Revenue beat(4)-0.92%
Min Revenue beat(4)-3.78%
Max Revenue beat(4)1.48%
Revenue beat(8)4
Avg Revenue beat(8)0.76%
Revenue beat(12)5
Avg Revenue beat(12)0.34%
Revenue beat(16)8
Avg Revenue beat(16)0.82%
PT rev (1m)-1.96%
PT rev (3m)-0.76%
EPS NQ rev (1m)6.62%
EPS NQ rev (3m)-682.68%
EPS NY rev (1m)-340.75%
EPS NY rev (3m)-145.79%
Revenue NQ rev (1m)-1.88%
Revenue NQ rev (3m)-4.22%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)0.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.7
P/FCF N/A
P/OCF N/A
P/B 130.24
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS4.19
BVpS0.09
TBVpS-1.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.68%
ROE -913.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.46%
FCFM N/A
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
F-Score5
Asset Turnover1.14
Health
Industry RankSector Rank
Debt/Equity 22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 91.05%
Cap/Sales 1.81%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.4
Quick Ratio 2.21
Altman-Z -0.55
F-Score5
WACC10.5%
ROIC/WACCN/A
Cap/Depr(3y)67.26%
Cap/Depr(5y)52.74%
Cap/Sales(3y)1.53%
Cap/Sales(5y)2.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.33%
EPS Next Y75.25%
EPS Next 2Y124.19%
EPS Next 3Y102.89%
EPS Next 5Y62.54%
Revenue 1Y (TTM)31.76%
Revenue growth 3Y38.74%
Revenue growth 5Y50.14%
Sales Q2Q%29.42%
Revenue Next Year31.82%
Revenue Next 2Y32.41%
Revenue Next 3Y29.86%
Revenue Next 5Y25.87%
EBIT growth 1Y32.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year804.84%
EBIT Next 3Y369.22%
EBIT Next 5Y256.22%
FCF growth 1Y35.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.07%
OCF growth 3YN/A
OCF growth 5YN/A